|Day's Range||43.2099 - 43.5530|
|52 Week Range||37.2000 - 45.5800|
|PE Ratio (TTM)||49.61|
|Dividend & Yield||1.95 (4.58%)|
|1y Target Est||N/A|
Gilead Sciences Inc said on Tuesday a combination of its experimental HIV drug with existing therapies met the main goal in four late-stage studies. Gilead, which already has approved treatments for HIV, is pinning its hope on the combination to better compete with Britain's GlaxoSmithKline Plc, which is working on two-drug treatment regimen for controlling the virus behind AIDS. The U.S. drugmaker evaluated the addition of its experimental drug, bictegravir, to emtricitabine/tenofovir alafenamide (FTC/TAF), which are already in use to treat HIV.
The Zacks Analyst Blog Highlights: Visa, General Electric, GlaxoSmithKline, Morgan Stanley and Abbott Laboratories
GlaxoSmithKline was among the gainers on Friday as the FTSE 100 set a new closing high. GSK was up 1.4 per cent to £16.41 after Berenberg turned positive with an £18.85 price trarget. "The market ...